Arman Fathizadeh, Erika M. V. Araujo, Nicholas T. Cockroft, Brett R. Beno, Keith R. Hornberger
{"title":"Toward Rational Design of Orally Bioavailable PROTACs: Development of a Fully Computational Oral Absorption Score","authors":"Arman Fathizadeh, Erika M. V. Araujo, Nicholas T. Cockroft, Brett R. Beno, Keith R. Hornberger","doi":"10.1021/acsmedchemlett.6c00305","DOIUrl":null,"url":null,"abstract":"<p>Achieving adequate oral absorption for proteolysis-targeting\r\nchimeras\r\n(PROTACs) remains challenging due to their size, polarity, and conformational\r\ncomplexity. While existing approaches often rely on physicochemical\r\nproperty space or chameleonicity-driven models, a generalizable framework\r\nfor guiding compound design prior to synthesis is lacking. Here, we\r\nintroduce comPASS, a fully computational scoring function derived\r\nfrom molecular dynamics-based descriptors that is designed to capture\r\nthe balance between molecular extension and exposed polarity through\r\nnormalized radius of gyration and three-dimensional polar surface\r\narea of PROTACs. Across mouse and rat data sets, comPASS shows consistent\r\npredictive performance and may facilitate prioritization of compounds\r\nat early design stages. We further show that within the data sets\r\nstudied, extended molecular geometries are associated with improved\r\nabsorption, when increased elongation is not driven solely by increases\r\nin molecular size. To assess the potential benefit of incorporating\r\nexperimental information, we also developed an enhanced variant, ePASS,\r\nwhich incorporates experimental polar surface area (EPSA) and lipophilicity\r\nterms consistent with prior approaches and shows promising predictive\r\nperformance relative to similar literature methods. Together, these\r\nresults establish practical guidance for presynthetic prioritization\r\nof PROTACs and provide a potential framework for guiding the design\r\nof orally absorbed PROTACs.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"17 10","pages":"2168–2174"},"PeriodicalIF":3.9000,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Medicinal Chemistry Letters","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsmedchemlett.6c00305","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Achieving adequate oral absorption for proteolysis-targeting
chimeras
(PROTACs) remains challenging due to their size, polarity, and conformational
complexity. While existing approaches often rely on physicochemical
property space or chameleonicity-driven models, a generalizable framework
for guiding compound design prior to synthesis is lacking. Here, we
introduce comPASS, a fully computational scoring function derived
from molecular dynamics-based descriptors that is designed to capture
the balance between molecular extension and exposed polarity through
normalized radius of gyration and three-dimensional polar surface
area of PROTACs. Across mouse and rat data sets, comPASS shows consistent
predictive performance and may facilitate prioritization of compounds
at early design stages. We further show that within the data sets
studied, extended molecular geometries are associated with improved
absorption, when increased elongation is not driven solely by increases
in molecular size. To assess the potential benefit of incorporating
experimental information, we also developed an enhanced variant, ePASS,
which incorporates experimental polar surface area (EPSA) and lipophilicity
terms consistent with prior approaches and shows promising predictive
performance relative to similar literature methods. Together, these
results establish practical guidance for presynthetic prioritization
of PROTACs and provide a potential framework for guiding the design
of orally absorbed PROTACs.
期刊介绍:
ACS Medicinal Chemistry Letters is interested in receiving manuscripts that discuss various aspects of medicinal chemistry. The journal will publish studies that pertain to a broad range of subject matter, including compound design and optimization, biological evaluation, drug delivery, imaging agents, and pharmacology of both small and large bioactive molecules. Specific areas include but are not limited to:
Identification, synthesis, and optimization of lead biologically active molecules and drugs (small molecules and biologics)
Biological characterization of new molecular entities in the context of drug discovery
Computational, cheminformatics, and structural studies for the identification or SAR analysis of bioactive molecules, ligands and their targets, etc.
Novel and improved methodologies, including radiation biochemistry, with broad application to medicinal chemistry
Discovery technologies for biologically active molecules from both synthetic and natural (plant and other) sources
Pharmacokinetic/pharmacodynamic studies that address mechanisms underlying drug disposition and response
Pharmacogenetic and pharmacogenomic studies used to enhance drug design and the translation of medicinal chemistry into the clinic
Mechanistic drug metabolism and regulation of metabolic enzyme gene expression
Chemistry patents relevant to the medicinal chemistry field.